| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Linan Ren, Feng Ju, Siyuan Liu, Yunjia Cai, Xiaokun Gang, Guixia Wan. New Perspectives on Obesity-Associated Nephropathy from Pathophysiology to Therapeutics: Revealing the Promise of GLP-1 RA Therapy. Drug design, development and therapy. vol 18. 2024-09-30. PMID:39347536. |
our emphasis underscores glucagon-like peptide-1 receptor agonists (glp-1 ras) as poised to emerge as pivotal therapeutic modalities for orn in forthcoming clinical avenues. |
2024-09-30 |
2024-10-02 |
human |
| Melissa Frangie Machado, Taylor Shunk, Grace Hansen, Charles Harvey, Baylee Fulford, Shane Hauf, Olivia Schuh, Matthew Kaldas, Elena Arcaroli, Justin Ortiz, Joseph De Gaetan. Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review. Cureus. vol 16. issue 8. 2024-09-12. PMID:39262529. |
while glp-1 receptor agonists (glp-1 ras) have traditionally been utilized to address insulin resistance, their potential application in treating polycystic ovary syndrome (pcos) has recently garnered attention. |
2024-09-12 |
2024-09-14 |
Not clear |
| Richard Le, Mau T Nguyen, Momina A Allahwala, James P Psaltis, Chinmay S Marathe, Jessica A Marathe, Peter J Psalti. Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs. Journal of clinical medicine. vol 13. issue 16. 2024-08-29. PMID:39200816. |
this narrative review examines the underlying pharmacology and clinical evidence behind the cardiovascular benefits of glp-1 ras, with particular focus on atherosclerotic cardiovascular disease. |
2024-08-29 |
2024-09-01 |
Not clear |
| Ahmed I Gad, Nevin F Ibrahim, Noura Almadani, Rasha Mahfouz, Hanaa A Nofal, Dina S El-Rafey, Hossam Tharwat Ali, Amr T El-Hawary, Ayman M E M Sade. Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial. Diseases (Basel, Switzerland). vol 12. issue 8. 2024-08-28. PMID:39195185. |
glp-1 receptor agonists (glp-1 ras) have been shown to improve glycemic control and insulin sensitivity and reduce body weight in obese patients with type 2 diabetes mellitus (t2d). |
2024-08-28 |
2024-08-30 |
Not clear |
| Madison Yates, Megan Supple, Melissa Macci. Reprint of: Impact of a pharmacist-led weight management service in a cardiology clinic. Journal of the American Pharmacists Association : JAPhA. 2024-08-11. PMID:39127937. |
glucagon-like peptide-1 receptor agonists (glp-1 ras) for weight management require frequent dose titration, patient education, and insurance coverage navigation, which pharmacists are well equipped to manage. |
2024-08-11 |
2024-08-13 |
Not clear |
| Michelantonio De Fano, Alberto Falorni, Massimo Malara, Francesca Porcellati, Carmine Giuseppe Fanell. Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review. Diabetes, metabolic syndrome and obesity : targets and therapy. vol 17. 2024-07-29. PMID:39072348. |
however, a very recent experts' consensus regarding the management of pasireotide-induced hyperglycemia in patients with acromegaly suggests the use of glp-1 ras as first line treatment (in suitable patients) and the use of sglt2-i as second line treatment in patients with high cardiovascular risk or renal disease. |
2024-07-29 |
2024-08-02 |
human |
| Davide Arillotta, Giuseppe Floresta, G Duccio Papanti Pelletier, Amira Guirguis, John Martin Corkery, Giovanni Martinotti, Fabrizio Schifan. Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach. Brain sciences. vol 14. issue 6. 2024-06-27. PMID:38928616. |
hence, this study explored the effects of glucagon-like peptide-1 receptor agonists (glp-1 ras) on substance and behavioral addictions, including alcohol, caffeine, nicotine, cannabis, psychostimulants, compulsive shopping, and sex drive/libido. |
2024-06-27 |
2024-06-29 |
Not clear |
| Alexander C Hill, Prasanna Santhanam, Caroline B Samples, Roberto Mitsui Akagi, Tariq Latif, Rodhan Khthi. Titration of Basal and Prandial Insulin Doses With the Initiation of Glucagon-Like Peptide-1 Receptor Agonist Therapy. Cureus. vol 16. issue 5. 2024-06-10. PMID:38854306. |
objective glucagon-like peptide-1 receptor agonists (glp-1 ras) have demonstrated significant efficacy in improving glycemic control in type 2 diabetes mellitus, which often results in decreased insulin dose requirements. |
2024-06-10 |
2024-06-14 |
Not clear |
| Raluca Oana Tipa, Daniela-Gabriela Balan, Mihai-Teodor Georgescu, Luciana Angela Ignat, Ileana Adela Vacaroiu, Dragos Eugen Georgescu, Laura Raducu, Doina Andrada Mihai, Liviu-Vasile Chiperi, Andra-Elena Balcangiu-Stroesc. A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies. International journal of molecular sciences. vol 25. issue 9. 2024-05-11. PMID:38732190. |
also, studies highlighted glp-1 ras' positive impact on olfactory function in obese individuals with type 2 diabetes, on neurodegenerative disorders, multiple sclerosis, and endotoxemia. |
2024-05-11 |
2024-05-27 |
mouse |
| Anastasia Adamou, Fotios Barkas, Haralampos J Milionis, George Ntaio. Glucagon-Like Receptor-1 Agonists and Stroke: a Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials. International journal of stroke : official journal of the International Stroke Society. 2024-04-27. PMID:38676552. |
this systematic review and meta-analysis investigated the impact of glp-1 ras on stroke risk. |
2024-04-27 |
2024-04-30 |
Not clear |
| Rayaz A Malik, Chii-Min Hwu, Anwar A Jammah, Juan M Arteaga-Díaz, Khier Djaballah, Valerie Pilorget, Agustina Alvarez, Carine Vera, Olga Vikulov. Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study. Diabetes, obesity & metabolism. 2024-04-19. PMID:38637981. |
to assess the impact of insulin glargine (100 u/ml) and lixisenatide (iglarlixi) fixed-ratio combination therapy on the overall management of glycaemia in patients with type 2 diabetes (t2d), previously inadequately controlled with oral antidiabetic drugs ± basal insulin or glucagon-like peptide-1 receptor agonists (glp-1 ras). |
2024-04-19 |
2024-04-21 |
Not clear |
| Zhenyu Liu, Huixi Kong, Baoyu Zhan. Narrative literature review of antidiabetic drugs' effect on hyperuricemia: elaborate on actual data and mechanisms. Endocrine connections. 2024-04-05. PMID:38579756. |
we find that insulin and dipeptidyl peptidase 4 inhibitor (dpp-4i) except linagliptin could increase the sua, and other drugs including metformin, thiazolidinediones (tzds), glucagon-like peptide-1 receptor agonists (glp-1 ras), linagliptin, sodium-glucose cotransporter 2 inhibitors (sglt2i) and α-glucosidase inhibitors have a reduction effect on sua. |
2024-04-05 |
2024-04-10 |
Not clear |
| Janet B McGill, Irl B Hirsch, Christopher G Parkin, Grazia Aleppo, Carol J Levy, James R Gavi. The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2024-04-04. PMID:38573469. |
in this narrative review, we discuss current evidence that supports glp-1 ra use in combination with insulin therapy and the potential pitfalls of reliance on glp-1 ras as a substitute for insulin therapy. |
2024-04-04 |
2024-04-06 |
Not clear |
| Stacy M Post, Susan Persk. The effect of GLP-1 receptor agonist use on negative evaluations of women with higher and lower body weight. International journal of obesity (2005). 2024-04-01. PMID:38561488. |
media reports suggest that glp-1 ras users often report feeling judged for taking a "shortcut" to lose weight, which may be related to negative stereotypes toward people with larger bodies. |
2024-04-01 |
2024-04-04 |
Not clear |
| Stacy M Post, Susan Persk. The effect of GLP-1 receptor agonist use on negative evaluations of women with higher and lower body weight. International journal of obesity (2005). 2024-04-01. PMID:38561488. |
media reports also describe negative attitudes about lean people who take glp-1 ras to enhance their appearance. |
2024-04-01 |
2024-04-04 |
Not clear |
| Esra Akcabag, Zinnet Sevval Aksoyalp, Feride Oner, Zeliha Bayram, Gul Ozbey, Cahit Nacitarhan, Sebahat Ozdem, Arda Tasatargil, Sadi S Ozde. Chronotropic Responses to GLP-1 Receptor Agonists and Sitagliptin in Atria from Diabetic Rats. Journal of cardiovascular pharmacology. 2024-03-28. PMID:38547520. |
glp-1 ras increase beating rates in isolated rat atrium through glp-1 receptor, nitric oxide, and cyclooxygenase pathways but not potassium channels and reactive oxygen radicals. |
2024-03-28 |
2024-03-31 |
rat |
| Adam G Tabak, Peter Kempler, Cristian Guja, Roy Eldor, Martin Haluzik, Tomasz Klupa, Nikolaos Papanas, Anca Pantea Stoian, Boris Mankovsk. Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2024-03-13. PMID:38472626. |
despite an increase in the use of glucagon-like peptide-1 receptor agonists (glp-1 ras), the experts urged timely insulin initiation for inadequate glycaemic control in pwt2d. |
2024-03-13 |
2024-03-15 |
Not clear |
| Augusto Lavalle Cobo, Walter Masson, Martin Lobo, Leandro Barbagelata, Ezequiel Forte, Pablo Corral, Juan P Nogueir. Ethnic/Racial and Geographic Disparities on Major Cardiovascular Events in Glucagon Like Peptide-1 receptor Agonists Trials: A Meta-Analysis. Current problems in cardiology. vol 48. issue 11. 2023-12-08. PMID:37422042. |
in this meta-analysis, we observed ethnic/racial and geographic disparities in mace reduction with glp-1 ras in cvots. |
2023-12-08 |
2023-12-17 |
Not clear |
| Madison Yates, Megan Supple, Melissa Macci. Impact of a Pharmacist-Led Weight Management Service in a Cardiology Clinic. Journal of the American Pharmacists Association : JAPhA. 2023-11-09. PMID:37944862. |
glucagon-like peptide-1 receptor agonists (glp-1 ras) for weight management require frequent dose titration, patient education, and insurance coverage navigation, which pharmacists are well-equipped to manage. |
2023-11-09 |
2023-11-20 |
Not clear |
| Fanjing Kong, Tianyu Wu, Jingyi Dai, Zhenwei Zhai, Jie Cai, Zhishan Zhu, Ying Xu, Tao Su. Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies. Frontiers in pharmacology. vol 14. 2023-09-29. PMID:37771725. |
the results showed that, in terms of behavioral tests, glp-1 ras could improve the learning and memory abilities of ad rodents; in terms of pathology, glp-1 ras could reduce aβ deposition and phosphorylated tau levels in the brains of ad rodents. |
2023-09-29 |
2023-10-07 |
Not clear |